Delcath Systems, Inc. (NASDAQ:DCTH) Short Interest Update

Delcath Systems, Inc. (NASDAQ:DCTH) was the target of a large decrease in short interest in the month of January. As of January 15th, there was short interest totalling 1,040,000 shares, a decrease of 23.0% from the December 31st total of 1,350,000 shares. Based on an average trading volume of 386,900 shares, the short-interest ratio is presently 2.7 days.

Delcath Systems Price Performance

Shares of DCTH stock opened at $15.60 on Friday. Delcath Systems has a 1 year low of $3.70 and a 1 year high of $16.44. The company has a market cap of $498.73 million, a PE ratio of -11.56 and a beta of 0.87. The stock’s 50 day simple moving average is $12.66 and its two-hundred day simple moving average is $10.44.

Analyst Ratings Changes

Several equities analysts have recently weighed in on DCTH shares. Craig Hallum increased their price target on Delcath Systems from $18.00 to $21.00 and gave the company a “buy” rating in a report on Friday, January 17th. Stephens reissued a “buy” rating on shares of Delcath Systems in a report on Friday, October 18th. StockNews.com raised Delcath Systems from a “sell” rating to a “hold” rating in a report on Friday, October 25th. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $21.00 target price on shares of Delcath Systems in a report on Friday, October 18th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $22.00 target price on shares of Delcath Systems in a report on Tuesday, January 14th. One research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $22.25.

Institutional Investors Weigh In On Delcath Systems

Several institutional investors have recently bought and sold shares of the company. Point72 Asia Singapore Pte. Ltd. purchased a new position in Delcath Systems in the 3rd quarter worth approximately $102,000. Barclays PLC purchased a new position in Delcath Systems in the 3rd quarter worth approximately $104,000. Jane Street Group LLC purchased a new position in Delcath Systems in the 3rd quarter worth approximately $110,000. Riverwater Partners LLC purchased a new position in Delcath Systems in the 3rd quarter worth approximately $161,000. Finally, Baader Bank Aktiengesellschaft purchased a new position in Delcath Systems in the 4th quarter worth approximately $204,000. 61.12% of the stock is currently owned by institutional investors and hedge funds.

Delcath Systems Company Profile

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company’s lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.